reported to be in use for a particular age group. Depending on the drug and target group, the proportion of respondents reporting the use of one standard concentration for a given drug ranged from 15% to 79%. The survey data informed and helped focus the USP expert committee's efforts to develop recommended standard concentrations for 10 high-alert drugs. Also presented in this article are general principles drafted by the USP committee to guide the development of local and national standard concentrations.
Conclusion.
The results of a national USP survey indicate that many institutions do not use standard i.v. infusion concentrations of commonly used high-risk medications in adult, pediatric, or neonatal patient populations.
T he U.S. Pharmacopeia (USP) Safe Medication Use Expert Committee (SMU EC), one of 62 expert committees in the USP Council of Experts, selected advocacy for increased use of standard i.v. concentrations, particularly those routinely used in pediatric patients, as an element of its work plan. The SMU EC consisted of 15 voting members (pharmacists, physicians, nurses, and researchers) and a nonvoting observer from the Food and Drug Administration's Office of Drug Safety.
Standardization and simplification are often-overlooked techniques for reducing the risks associated with medication use at a number of stages, including prescribing, preparation, dispensing, and administration. In recent years, several factors have drawn increased attention to the use of standardized i.v. concentrations as a medication safety strategy.
One of the original National Patient Safety Goals (NPSGs) issued by the Joint Commission in 2003 to improve the safety of the use of highalert medications (part of Goal 3B) addressed the need to standardize and limit the number of drug concentrations available within a health care organization. 1 As part of the rationale and implementation expectations provided for Goal 3B, the Joint Commission emphasized that the "rule of six" process (i.e., creating individualized i.v. concentrations for pediatric patients based on body weight) did not meet the requirements of this NPSG. An extension to the process was made to give organizations a deadline of December 2008 to complete the transition to standardized i.v. concentrations for use in pediatric and neonatal patients.
In 2009, the NPSGs underwent an extensive review. The element of performance related to i.v. drug concentrations is now part of the medication management standards (MM01.02.01): "The hospital standardizes and limits the number of drug concentrations available to meet patient care needs." 3 In addition, a Joint Commission sentinel event alert emphasized the need to "limit the number of concentrations and dose strengths of high-alert medications to the minimum needed to provide safe care." 4 Although increased attention from the Joint Commission has decreased the use of individualized concentrations in favor of more standardization, particularly in pediatric care settings, the level of standardization achieved remains unclear.
The use of intelligent infusion devices (smart pumps) with "hard" and "soft" dosing limits and the use of patient-specific rate alarms have increased interest in and promoted the use of standard i.v. concentrations because they necessitate the development of a catalog of acceptable medications and concentrations (the drug library). However, a review of information from 100 hospitals using a single manufacturer's infusion device several years ago showed substantial unnecessary variation in i.v. medication practices, including names per drug, concentrations for continuous and bolus dosing, and dosing limits. 5 In 2008, the American Society of Health-System Pharmacists (ASHP) House of Delegates approved a policy statement supporting the development of "nationally standardized drug concentrations and dosing units for commonly used high-risk drugs that are given as continuous infusions." 6 In addition, a July 2008 summit on preventing patient harm and death due to i.v. medication errors resulted in a number of proposals, including a statement that nationally standardized infusion concentrations should be required for medications frequently associated with harm or death. 7 The work of the SMU EC supports that vision. The committee determined that a survey of U.S. hospitals was an important first step in efforts to identify commonly used standard concentrations and to determine the extent of variability in current practice.
The increased standardization of i.v. infusion concentrations nationwide would extend the safety benefits of institutionwide or systemwide standard concentrations and also create important economies of scale; this is particularly important for pediatric concentrations of infusion medications, for which almost no admixtures are commercially available. The use of commercially prepared admixtures provides an additional measure of safety beyond the use of standard concentrations because the risks of compounding errors and potentially infectious contamination are lower in a manufacturing setting than when individual doses are prepared at the institutional level. In addition, standardization can reduce costs related to staff time and the disposal of compounded sterile products that are not used before their expiration dates.
This article summarizes the results of a survey conducted by the SMU EC in the spring of 2008 to assess the extent of the use of standard i.v. drug concentrations in U.S. hospitals and health systems. In addition, general principles to guide the development of local and national standard concentrations for i.v. admixtures are presented.
Methods
A survey was developed by the SMU EC to obtain a comprehensive snapshot of currently used i.v. concentrations and to identify opportunities for improvement in standardizing concentrations for adult, pediatric, and neonatal infusions and line flushes. The survey consisted of a single screening question, items eliciting information on survey respondents (facility type and setting, number of beds, and geographic region), and a request for a list of standardized or routinely used i.v. concentrations in use within the respondent's institution or health system. The screening question asked, "Has your organization established standard concentrations for commonly used i.v. infusions and line flushes (e.g., designed to meet the needs of 90% or more of your patients)?"
In April 2008, the USP survey was sent out electronically to approximately 3500 U.S. hospital and health-system pharmacy directors via a broadcast e-mail from ASHP. All individuals in the targeted group for whom ASHP had a current direct e-mail address were included. Survey respondents had the option of completing and submitting the one-page survey response form electronically or printing the form and returning it by fax. Respondents were instructed to attach, fax, or separately e-mail a list of standardized or routinely used i.v. preparations to USP. As an incentive to respond, individuals completing the survey were entered in a drawing for an Apple iPod and could receive the survey results. The submitted lists of i.v. medications and concentrations were converted to a standard format (drug and concentration in milligrams per milliliter, micrograms per milliliter, or units per milliliter) to facilitate data analysis and report generation. Reported i.v. concentrations specific to pediatric and neonatal populations were analyzed separately from adult concentrations. If the use of more than one concentration for a medication was reported, this information was collated and further analyzed descriptively. The i.v. concentrations reported were compared with existing commercially available (premixed) infusion concentrations and concentrations recommended in the product package insert. A set of general principles was developed by the SMU EC to guide the selection of concentrations that would best meet the needs of adult, pediatric, or neonatal patients and, when possible, all three patient populations.
Results
More than 350 survey responses were received by fax or e-mail. There were 174 affirmative responses to the screening question and 2 negative responses; the other respondents did Tables  2, 3 , and 4 summarize key information about the most common standard concentrations established for adult, pediatric, and neonatal patients, respectively; Table 5 presents proposed national standard concentrations.
Discussion
The survey response rate was disappointing (a 10% overall response, with less than 7% of respondents providing lists of i.v. concentrations); this low response rate might indicate even less emphasis on the use of standard i.v. concentrations at nonresponding organizations. To minimize the electronic communication burden on this frequently surveyed group, the survey was not sent out more than once. Because the respondents included large in-tegrated health systems, the actual number of hospitals represented was larger than the number of responses. The sample obtained and the diversity of respondents were sufficient to achieve a much better understanding of how standardized concentrations are being used on a national level than has been documented previously.
While information on current practices is valuable, selecting the mode from a national survey is not the optimal way to identify a national standard concentration. A subcommittee of the SMU EC developed the first draft of a series of general principles for selecting standard infusion concentrations. It was established that a standard concentration should meet the needs of at least 90% of the target patient population. Although the uniform use of a single standard i.v. concen- Mode of responses received. c This variation is thought to be due to three apparent typographical errors; premixed vials only available as 10 mg/mL. tration would be ideal in most cases, it is recognized that under certain circumstances (e.g., the need for fluid restriction, extreme-outlier values based on patient weight or dose), the use of a standard concentration might result in excessive fluid volume or an infusion rate too low for the capabilities of the infusion device. The recommendations were refined through discussion during several convened meetings of the SMU EC, and consensus was obtained on a number of points:
Concentrations of Selected Drugs Used for
• Concentrations already available as commercially premixed infusions are preferentially considered to be the standard concentrations.
• Concentrations that are in wide use across a number of institutions (as measured by the spring 2008 survey reported in this article) are preferentially considered for a national standard.
• An adult standard concentration that also meets the needs of a large percentage of pediatric patients (e.g., those weighing more than 40 kg) is particularly desirable.
• Concentrations that simplify dose titration or i.v. rate calculations (e.g., heparin 100 units/mL, insulin 1 unit/ mL) are highly desirable. • An i.v. concentration must be well tolerated for infusion by peripheral vein (unless the medication is exclusively infused through a central line).
• A selected standard concentration should allow a measurable infusion rate while avoiding excessive fluid intake when administered in the usual dosage range.
• "Double-concentrate" infusions to address fluid overload should be minimized.
• When an alternative to the standard concentration is used, a maximally
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Concentrations of Selected Drugs Used for Pediatric Patients at Surveyed Institutions (n = 55)

Concentrations of Selected Drugs
• Premixed i.v. infusion medications should be available in a sodium chloride base solution if stable (rather than dextrose 5%, for example) to allow the greatest usability of the product.
Many of the standard concentrations commonly reported by the survey respondents failed to meet these general principles, particularly the goal of minimizing the use of several adult standard concentrations for a single drug. Participants at the i.v. medication safety summit recommended that national standards for i.v. drug use, including standardized concentrations and commercially available concentrations, be developed by professional associations representing the health care disciplines and patient-safety organizations. 6 Moreover, summit attendees recommended that an initial set of standards should include at least 10 drugs, preferably high-alert products already available in readyto-administer form; such a list would be expanded into a comprehensive reference that should be nationally adopted. The SMU EC was involved in recommending standards for the first 10 high-alert products. The draft general principles contained in this report provide a good starting point for a national discussion on a comprehensive reference of standard concentrations. Because of USP's role as a standard-setting body and a convener of stakeholders in the health professions and the pharmaceutical industry, USP could play an important role in advancing this agenda. ing to improve the care of newborns, recently published a list of neonatal drug infusion concentrations and are urging all hospitals that treat newborns to adopt them as standard. 8 In addition, the Artemis Pediatric Initiative is a collaborative effort of two physicians (one is the inventor of the Broselow Tape) and the Pediatric Pharmacy Advocacy Group to develop a simple, safe, and effective international standard for acute pediatric administration of drugs. 9 Identifying the i.v. infusion concentrations most frequently used at institutions around the country is an important first step in developing the consensus needed for the adoption of national standards. Further consolidation of the concentrations used will increase the likelihood that commercial manufacturers will make products available in premixed (ready-to-administer) infusions. USP could serve as a convener of stakeholders, working with the health professions, professional organizations, and patient-safety organizations to make nationally standardized i.v. concentrations a reality. Practitioners should not lose sight of the fact that there will always be a need for nonstandard concentrations for a small minority of patients.
Conclusion
The results of a national USP survey indicate that many institutions do not use standard i.v. infusion concentrations of commonly used highrisk medications in adult, pediatric, or neonatal patient populations.
